← Back to Search

Educational and Feedback Interventions for Bronchiolitis

N/A

Recruiting

Led By Rinad S Beidas, PhD

Research Sponsored by Children's Hospital of Philadelphia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Infants and children 2 months through 23 months old

Hospitalized on non-ICU wards participating in the trial

Must not have

Neuromuscular disease

Immunodeficiency

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 years

Awards & highlights

No Placebo-Only Group

Summary

This trial will help find the best way to stop using continuous pulse oximetry for children with bronchiolitis who don't need extra oxygen.

Who is the study for?

The EMO Trial is for English-speaking nurses, physicians, and hospital administrators who have cared for bronchiolitis patients. It includes infants and children aged 2-23 months hospitalized with a primary diagnosis of bronchiolitis on non-ICU wards. Exclusions are extreme prematurity, cardiac disease, chronic lung conditions, immunodeficiency or current severe illness like COVID-19.

What is being tested?

This study tests strategies to reduce unnecessary continuous pulse oximetry monitoring in children with bronchiolitis not needing supplemental oxygen. Interventions include educational outreach, audit & feedback at unit and individual levels, and integrating clinical pathways into electronic health records.

What are the potential side effects?

Since the interventions involve process changes rather than medications or medical procedures, traditional side effects are not applicable. However, there may be indirect effects on patient care routines or outcomes which will be monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My child is between 2 and 23 months old.

Select...

I am currently hospitalized but not in the ICU.

Select...

My latest doctor's note says I have bronchiolitis.

Select...

I need at least 2 liters per minute of extra oxygen to breathe.

Select...

I do not need extra oxygen to breathe normally.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a neuromuscular disease.

Select...

I have a weakened immune system.

Select...

I have or might have COVID-19 or its related severe complications.

Select...

I have a heart condition.

Select...

I have high blood pressure in the lungs.

Select...

I have a long-term lung condition.

Select...

I have or might have COVID-19.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Sustainability of guideline-concordant deimplementation of continuous pulse oximetry monitoring

Secondary study objectives

Acceptability of deimplementation

Appropriateness of deimplementation

Cost of deimplementation strategies

+5 more

Other study objectives

Exploratory long-term sustainability

Implementation Climate

Implementation Leadership

+6 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Unlearning + SubstitutionExperimental Treatment4 Interventions

Includes educational outreach, audit \& feedback, and an electronic health record-integrated clinical pathway to support appropriate use of pulse oximetry.

Group II: Unlearning OnlyActive Control3 Interventions

Includes educational outreach and audit \& feedback.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Educational Outreach

2015

N/A

~210

0 / 12Eligibility criteria met